Finding New Ways to Treat Lung Cancer
Identifying Metabolic Vulnerabilities in Lung Cancer
This research aims to discover new weaknesses in lung cancer cells to develop more effective treatments for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11128780 on NIH RePORTER |
What this research studies
Lung cancer remains a leading cause of cancer deaths, and while some treatments like immunotherapy help, many patients, especially those with advanced or small cell lung cancer, need better options. Our team is working to understand the unique biological processes that fuel lung cancer growth. By studying these processes, we hope to find new targets for medications that can either be used alone or combined with existing therapies to improve patient outcomes. We use advanced laboratory models and cutting-edge techniques to uncover these potential new treatment strategies.
Who could benefit from this research
Good fit: This foundational research is for future patients with lung cancer, especially those with metastatic disease or small cell lung cancer, who may benefit from new therapies.
Not a fit: Patients seeking immediate direct treatment or clinical trial participation will not find a direct benefit from this early-stage laboratory research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new and more effective treatment options for patients with lung cancer, particularly those with advanced or small cell types.
How similar studies have performed: While existing treatments like tyrosine kinase inhibitors and immunotherapy have shown success in some lung cancer patients, this approach seeks novel therapeutic strategies to address current treatment gaps.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Flores, Elsa R — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Flores, Elsa R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.